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Available online 21 January 2014EU Directive 2010/63/EU regarding the protection of experimental animals came into force in
November 2010 with an obligation for EU member states to incorporate its requirements into their
respective national legislations by 1st of January 2013. The directive stipulates the application of in
vitro methods to replace animal experiments whenever such an in vitro method exits and is
recognized by EU legislation. The monocyte activation test (MAT) for the detection and
quantification of pyrogenic contamination in medicines is recognized by the European Directorate
for the Quality of Medicines & Health Care (EDQM) and was published in the European
Pharmacopeia (Pharm. Eur.) in April 2010. The methodology described here facilitates the use of
the MAT by making monocytes available, in the form of cryopreserved human peripheral blood
mononuclear cells (PBMCs). We have developed and qualified a procedure to prepare functional
monocytes in the formof PBMCs from the leukocyte filters that are used for the separationof blood in
blood donation centers. Once used, these filters are normally treated as biological waste. Here we
describe the procedures that are critical for the successful cryopreservation of PBMCs, demonstrate
protection of PBMC functionality using various ligands for the toll-like receptors (TLRs) that mediate
pyrogenic responses, report validationof themethodology for linearity, precision and robustness and
show examples of the practical application of cryopreserved in MATs with samples of drugs and
vaccines. Another application of cryopreserved PBMCs, only mentioned here, is to serve as an
alternative to freshly isolated PBMCs in tests for unwanted intrinsic pro-inflammatory activities of
newbiological therapeutics. Such tests use PBMCs or PBMCs over a layer of endothelial cells to detect
(unwanted) cytokine release, PBMCs beingmore suited to this purpose than tests usingwhole blood.
© 2014 The Authors. Published by Elsevier B.V.Open access under CC BY-NC-SA license. Keywords:
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Pyrogens are a class of chemically heterogeneous fever-
inducing substances derived from gram-negative and gram-
positive bacteria (Moreillon and Majcherczyk, 2003), viruses,
fungi and other sources. During an immune response,monocytes
and macrophages produce endogenous pyrogens such as prosta-
glandins and the pro-inflammatory cytokines interleukin-1β
(IL-1β), interleukin-6 (IL-6), and tumor necrosis factor-alpha
(TNFα), which are used as readouts to measure the magnitude
of the immune response (Biswas and Lopez-Collanzo, 2009).
Depending on the type and quantity of pyrogen(s) that
constitute the challenge and the sensitivity of the individual
challenged, life-threatening consequences can ensue. Therefore,C-SA license. 
Table 1
Overview of the critical parameters.
Critical parameter Options
evaluated
Acceptance criteria
for PBMCs
Outcome/
recommendation
Cryoprotectant 10 different cryo-protectant mixtures
evaluated
Recovery N 80%
Viability N 95%
Appropriate response to stimuli
Optimum mixture: 50% human serum
AB + 43% RPMI 1640 + 7% DMSO
Freezing ramp Rate-controlled cooling. Swift handling
when PBMCs in liquid
Viability N 95%
Appropriate response to stimuli
Initially 10°–15 °C, decrease to +4 °C,
then slowly to −8 °C, then faster to −80 °C
Thawing Different temperatures
and times
Viability N 95%
Appropriate Response to stimuli
Optimum:
Rapid thawing at 37 °C within 1 min
Pre-incubation No pre-incubation or 60 min
pre-incubation at 37 °C
Appropriate response to stimuli Pre-incubation has no advantage
PBMC isolation agent With vs. without Lymphoprep Appropriate response to stimuli Lymphoprep has no influence
Blood anti-coagulant Na-Citrate vs. low molecular
weight heparin
Appropriate response to stimuli No difference observed
PBMC cell concentration 0.7, 1.0, 1.5 million
cells per mL
Appropriate response to stimuli 1.0 million cells per mL recommended
Overview of general and critical parameters to be respected preliminary when producing cryopreserved PBMCs.
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obligatory test for pyrogens (Poole et al., 1988).
The rabbit pyrogen test (European Pharmacopeia 2.6.8;
United States Pharmacopeia b151N) and the bacterial endo-
toxins test, also called BET or LAL test (European Pharmacopeia
2.6.14; United States Pharmacopeia b85N) have been applied in
QC of parenteral drugs for more than 60 and 30 years,
respectively. Nowadays, a growing need for new methods is
explained by the constantly increasing production of biological
compounds and medical devices resulting from the success of
biotechnology and nanoscience.
Multiple limitations of the existing methods and accumula-
tion of a scientific knowledge in the field of immunology have
contributed to the development of alternative methods for
pyrogen detection. Since the monocyte activation test has
proven to be a suitable alternative in pyrogen testing, several
scientific groups, including our group at Novartis, have focused
on its development (GainesDas et al., 2004). Decisive advantages
of the MAT, such as in vitro application, high sensitivity and
recognition of a wide range of pyrogens, led to the acceptance of
the MAT for pyrogen testing by the European Pharmacopeia, in
April 2010. However, the widespread introduction and applica-
tion of MAT encounters regulatory and practical restrictions
mostly related to the use of freshhumanbloodormonocytes and
the associated phlebotomy. Therefore, the present study de-
scribes a phlebotomy-free alternative by exploring the possibility
of usingmonocytes isolated from lymphocyte filters (Ebner et al.,
2001). These filters are usually treated as bio-waste in hospitals
and blood donation centers (Stegmayr, 2005). Seeking to avoid
the handling of fresh human blood in the BL2-level laboratories
usually involved in pyrogen testing, we have developed an MAT
using cryopreserved PBMCs.
The formal validation of this methodology was per-
formed in accordance with the guidelines provided by the
European Centre for the Validation of Alternative Methods
(Hoffmann et al., 2005; Schindler et al., 2006) and was
additionally validated against specific parameters, as
proposed by ICH guidelines for the validation of analytical
methods (ICH, Guidelines on validation of analytical
procedures, Q2 (R1) 1995). Additionally, the method was
required to fulfill local acceptance criteria for the evalua-
tion of reliability and relevance of in vitro methods.Over the past 15 years of practical application of the MAT in
routine QC analytics, we have learned that MAT with isolated
fresh PBMCs and IL-6 as the readout is the one variant of theMAT
which produces reliable results for the detection of endotoxin
and non-endotoxin pyrogens in pharmaceutical preparations.
2. Materials and methods
2.1. Critical parameters and acceptance criteria for the
preparation and use of cryo-preserved PBMCs
The parameters for production of cryopreserved PBMCs
were evaluated to determine their influence on the perfor-
mance of cryopreserved PBMCs in monocyte activation tests:
Table 1 gives an overview of the findings with more details
given in Sections 2.1.1 to 2.1.7.
2.1.1. Cryoprotectant
Options: Cryoprotective mixture containing various agents in
different ratios (RPMI medium 0–45%, autologous
plasma 10–90%, AB serum 0–93%, DMSO 5–10%,
Hydroxyethyl starch 6% and trehalose 1.14%).
Criteria Recovery: (PBMC frozen/PBMC thawed ~80%), viability
(viable PBMCs within recovered cells, N95%), re-
sponse to reference standard endotoxin and test
substances (optical density in IL-6 ELISA 0.5–3.0),
practical difficulties (inverse rating).
Observations: Three promising cryoprotective mixtures were
identified and compared based on the successful
fulfillment of the given criteria. The most suitable
cryoprotective mixture was elected for all further
experimentations (for details see Section 2.2.3
Cryopreservation of PBMCs). Cryopreserved PBMCs
frozen with two different cryoprotective mixtures,
both containing 1.14% of trehalose, failed to detect
pyrogenic contaminations inMATdespite acceptable
viability. Addition of 6% of hydroxyethyl starch to
the cryoprotective mixture led to PBMCs which
demonstrated inverse relationship between signal
intensity and pyrogen concentration.
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Options: Cooling program. Using the computerized freezing
machine KRYO-560 we developed a rate-controlled
freezing program paying particular attention to the
zero degree point and handling of PBMCs directly
before cryopreservation.
Criteria: Cell viability after thawing (N95%) and PBMC
performance in MAT (pass/fail). Under the term of
“PBMC performance in MAT”we mean the ability of
PBMCs to detect pyrogenic contamination in test
samples by releasing IL-6.
Observations: Attention to temperature conditions and rapid
handling of PBMCs already suspended in the cryo-
protectivemixture appeared to be decisive factors for
later cell performance in our experiments. Therefore,
we recommend either procession of small numbers
of PBMCs at a time or maintenance of the resuspend-
ed cells at 2–8 °C. Intermediate storage in ice was
counterproductive. For the programming of the
freezing ramp we recommend that the starting
temperature is initially decreased to 10 °C–15 °C
and then slowly decreased to +4 °C and to−8 °C.2.1.3. Thawing procedure
Options: Conditions of thawing, such as temperature and
time of thawing were evaluated with particular
attention to the contact time with DMSO in the
cryoprotectant immediately after thawing.
Criteria: Cell viability after thawing (N95%) and PBMC
performance in MAT (pass/fail).
Observations: Rapid thawing at+37 °Cwithin 1 min led to the
highest PBMC viability and optimum dose–response
curves with reference endotoxin in the MAT. In
contrast, slow thawing resulting in prolonged contact
time with DMSO (in liquid stage) leads to low cell
viability and unsatisfactory performance of cells in the
MAT.2.1.4. Effect of pre-incubation
Options: Pre-incubation. In order to minimize possible cell
distress resulting from the thawing and washing
procedure, cells were pre-incubated for 60 min at
37 °C before seeding into microplates and coming
into contact with pyrogens.
Criteria: PBMC performance in MAT (pass/fail).
Observations: Pre-incubation of thawed PBMCs (1 m/mL,37C, 5% CO2, 60 min) led to slightly decreased
responsiveness of PBMCs to the activation stimuli
and resulted in the release of less IL-6 in response to
thepyrogen-contaminated samples, as comparedwith
the PBMCs that had not been pre-incubated. We
observed no difference between pre-incubated and
non pre-incubated PBMCs when non-contaminated
substances were tested. We cannot exclude that the
small difference in the IL-6 signal was related to the
number of cells in suspension and not solely to the
pre-incubation step itself.2.1.5. Effect of PBMC isolation agent
Options: Effect of Lymphoprep. We tested the chemically
complex substance Lymphoprep, used for the
isolation of PBMCs, for its possible influence on
responsiveness of cryopreserved PBMCs used in
the MAT.
Criteria: PBMC performance in MAT (pass/fail).
Observations: The isolation of PBMCs from lymphocyte filterswas performed with and without application of
Lymphoprep according to themanufacturer's instruc-
tions. Cell number, cryopreservation and thawing
procedures, as well as MAT settings were identical.
Experimental results demonstrated that the use of
Lymphoprep as an isolation agent is not a contribut-
ing factor to the responsiveness of cryopreserved
PBMCs to pyrogens.2.1.6. Effect of blood anti-coagulating agents in PBMC isolation
Options: Effect of Fragmin (heparin) and sodium citrate. We
tested these two commonly used blood anti-
coagulation agents in order to assess their possible
effect on the capability of cryopreserved PBMCs to
recognize pyrogenic contamination in the MAT.
Criteria: PBMC performance in MAT (pass/fail).
Observations: Isolation of PBMCs was performed using either
Fragmin (heparin) or sodium citrate as blood anti-
coagulant. Cell number, cryopreservation and
thawing procedures, as well as MAT settings
were identical. The MAT was performed with
freshly isolated as well as cryopreserved PBMCs
from the same donor. Experimental results using
fresh PBMCs demonstrated that the use of sodium
citrate led to increased responsiveness of PBMCs to
activation stimuli in comparison to Fragmin. Howev-
er, similar experiments using cryopreserved PBMCs
didn't show any significant difference in performance
whichever anti-coagulant was used.2.1.7. Effect of PBMC cell concentration
Options: Effect of cell count. We tested various PBMC
concentrations to assess the limit of acceptable
cell count to recognize pyrogenic contaminations
in MAT.
Criteria: PBMC performance in MAT (pass/fail).
Observations: The cell count used for seeding in MAT provedas a critical factor in detection of contaminations
in test samples. We recommend using 1 million
PBMCs/mL for seeding as a lower limit. Taking into
account 80% as an average cell recovery after
cryopreservation in our experiments, it is advisable
to freeze 1.2 × 107 cells/mL of PBMCs per cryovial.
Freezing of high cell counts per mL proved contra
productive due to the formation of cell aggregates
during thawing.
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comparison with fresh PBMCs
All work described below was performed according to
general GMP rules and standard operating procedures of the
various methods as made available by ECVAM (http://ecvam.
jrc.it). Internal testingmonographs for drug substance and for a
chemical intermediate, respectively, were used during valida-
tion using an example of a fermentation-manufactured drug
substance. An internal testmethodwas developed for a vaccine
preparation and used during further experimental work on the
sample-specific adjustment of the validated methodology.
Preparation and use of cryopreserved monocytes were per-
formed according to internal laboratory instructions. Reagents
and consumables were purchased as sterile and pyrogen-free,
and non-specified reagents were pro analysis grade.
2.2.1. Endotoxin reference preparation and other Toll-like
receptor ligands
USP reference standard endotoxin from E. coli (USP,
Rockville, MD, USA, 10,000 EU/vial) was used in a geometric
dilution in the range of 0.063–2 EU/mL. Other TLR ligands
included endotoxin from Pseudomonas aeruginosa (kindly
donated by NIBSC, UK), Heat killed Staphylococcus aureus
(Invivogen, San Diego, CA, USA, Cat. # tlrl-hksa), peptidoglycan
from S. aureus (Invivogen, San Diego, CA, USA Cat. # tlrl-pgnsa,),
purified Flagellin from Bacillus subtilis (Invivogen,San Diego, CA,
USA, Cat. # tlrl-bsfla) and PAM3CSK4, synthetic bacterial
lipoprotein (Invivogen, San Diego, CA, USA, Cat. # tlrl-pms).
Details on the TLR ligands are summarized in Table 2. Column
“Endotoxin by LAL” refers to the endotoxin-trace analysis
performed in our laboratory using bacterial endotoxins test as
described previously (Straube et al., 2005).
2.2.2. Isolation of monocytes from lymphocyte ﬁlters
Used leukocyte filters were collected at the Blood
Donation Centre Basel. Filters, each containing lymphocytes
from 450 mL of fresh human blood, were maintained at 5–
20 °C and processed within 4 h. They were (reversely) rinsed
3 times with 30 mL of 2–8 °C pre-cooled rinsing buffer
containing 5 mM EDTA (Sigma-Aldrich, Steinheim, Germany
Cat # E0399) in Dulbecco's phosphate buffered saline
(Invitrogen, Life Technologies Europe B.V. Zug, Switzerland,
Cat # 14190). The rinses were collected and yielded PBMCs
containing about 20% monocytes.
PBMCs were isolated by gradient centrifugation using
Lymphoprep (Axis-Shield PoC AS, Oslo, Norway, Cat #
1114544) according to the manufacturer's instructions.Table 2
TLR Ligands and their specifications.
Toll like receptor (TLR) TLR trigger
TLR 4 USP reference endotoxin
TLR 4 Endotoxin from P. aeruginosa
TLR 2 Heat-killed S. aureus
TLR 2/TLR 6 Peptidoglycan from S. aureus
TLR 2/TLR 1 Synthetic TLR ligand PAM3CSK4
TLR 5 Flagellin from B. subtilis
Summary on commercially available TLR ligands used in our experiments. Column
laboratory using bacterial endotoxins test.Briefly, 30 mL of the PBMC reflux preparation was trans-
ferred to each of three 50 mL Blue Max tubes (Becton
Dickinson, Falcon, Durham, NC, USA, Cat # 352070), and
then 20 mL of Lymphoprep was added to each tube to form a
lower layer. Layer formation is critical for the maximum
recovery of PBMCs and should be performed using a 10 mL
sterile plastic pipette with the cotton removed. Following the
centrifugation at 340 ×g for 45 min (18–25 °C), the PBMCs
formed a white band which was aspirated and transferred to
a new Blue Max tube. The tube was filled up to 45 mL with
Dulbecco's phosphate buffered saline (DPBS) and centrifuged
at 240 ×g for 10 min (18–25 °C). The supernatant was
discarded and the cell pellet resuspended again in 45 mL of
DPBS. Out of this suspension a cell count using a Neubauer
hemocytometer was performed. After centrifugation, the
supernatant of the second washing was discarded. The
isolated monocytes were then available in the form of a
PBMC cell sediment with a known number of cells.
2.2.3. Cryopreservation of PBMCs
The PBMC cell sediment containing the monocytes was
subjected to immediate programmed cryopreservation. The
suspension was prepared by adding pre-cooled (2–8 °C)
human AB serum (Sigma-Aldrich, Steinheim, Germany, Cat #
H-4522) to the cell sediment in a slow manner, by dropwise
addition via the wall of the tube. The used volume of
human serum AB was chosen to produce a cell count of
2.4 × 107 cells/mL. Separately, cryoprotective liquid was
prepared by mixing 3.25 mL DMSO (Sigma-Aldrich, Cat #
D8418) with 16.55 mL of pre-cooled (2–8 °C) RPMI 1640
Medium (Invitrogen, Cat # No 21875-034) supplemented
with 200 μl L-glutamine 200 mM (Invitrogen, Cat # 25030-
032). Cryoprotective liquid (the same volume as for human
serum AB was used) was slowly added to the PBMC
suspension in human AB serum and the resuspended mixture
was rapidly aliquoted into cryovials (2.0 mL, Corning, New
York, USA, Cat # 430659) at approx. 1.2 × 107 cells/cryovial.
Temperature range, speed and sequence of preparing and
adding reagents proved to be crucial to the viability of
monocytes. Samples were frozen using the freezing machine
KRYO-560 (Planer, Sunbury, UK) under the following pro-
grammed conditions:starting temperature +13.0 °C,
step 1 −1.0 °C/min to +4.0 °C chamber,
step 2 - hold for 10 s,
step 3 −0.5 °C/min to −8.0 °C sample,
step 4 −1.0 °C/min to −40.0 °C chamber,
step 5 −2.0 °C/min to −80.0 °C chamber,
step 6 - hold 1.0 min.Endotoxin by LAL Stock solution
Not done 2000 EU/mL
Not done 40.000 EU/mL
At 2 × 109 cells/mL b0.1 EU/mL 1 × 1010 cells/mL
At 20 μg/mL b0.132 EU/mL 200 μg/mL
At 100 μg/mL b0.1 EU/mL 1 mg/mL
At 100 μg/mL b0.019 EU/mL 100 μg/mL
“Endotoxin by LAL” refers to the endotoxin trace analysis performed in our
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for approx. one week and then transferred into a liquid nitrogen
tank.
2.2.4. Thawing of the PBMCs and cell culture
Cryopreserved PBMCs were thawed in a water bath at
37 ± 1 °C for 1–2 min until only a tiny piece of ice remained
and then transferred to a 50 mL Blue Max tube for washing.
The washing steps were performed with not more than
1.5 × 107 cells per 50 mL tube. Washing medium at 2–8 °C
(RPMI 1640 Medium with 1% human serum AB) was added
dropwise (1 drop/10 s for the first 30 s, then 1 drop/3–5 s)
into each tube while swirling, then the cells were centrifuged
at 240 ×g, 10 °C, for 5 min. The cells were resuspended
in RPMI 1640 with 1% human AB serum, 2% of Penicillin
(10,000 IU/mL), Streptomycin (10,000 μg/mL) and 1%
L-glutamine (200 mM).
2.2.5. Immunoﬂuorescence and visual light microscopy
Both assays were performed in a GMP setting during the
pre-validation phase and aimed to collect additional infor-
mation on factors of importance for the ability of thawed
PBMCs to detect pyrogenic contamination in the internal
Novartis substances.
For immunofluorescence assay, thawed PBMCs were
incubated with 1.0 EU/mL of USP reference standard endo-
toxin from E. coli (USP, Rockville, MD, USA, 10,000 EU/vial) as
a positive control and with in-house substances for testing.
The cells were fixed in 1% paraformaldehyde in DPBS for at
least 15 min at 4 °C, permeabilized using 0.2% Triton-X
(prepared in DPBS containing 1% bovine serum albumin
BSA), and then incubated with primary antibodies. The
antibodies were diluted in DPBS containing 1% BSA: anti-
p-65 1:100 (Santa Cruz Biotechnology CA, USA).
Thereafter, the cells were washed three times with DPBS
and incubated for 1 h with affinity-purified Alexa-Fluor 488
goat-anti-rabbit IgG (H + L) (Invitrogen, Molecular Probes,
Basel, Switzerland; diluted 1:1500). Nuclei were counter-
stained with DRAQ5™ (Alexis; diluted 1:3000), and visual-
ized by Leica TCS SP scanning confocal microscope (Leica
Microsystems Heidelberg GmbH), and analyzed with ImageJ
1.37 t Software (NIH, USA).
For light microscopy, portions of the thawed PBMCs
originating from 4 individuals were cultivated in complete
RPMI 1640medium for 10 days. Lightmicroscopy pictureswere
taken on a Leica DM2500 microscope (Leica Microsystems
(Schweiz) AG, Heerbrugg, Switzerland) equipped with an
Olympus XC30 Camera (Olympus Schweiz AG, Volketswil,
Switzerland).
2.2.6. MAT cell culture and IL-6 detection
PBMC cell suspension at 1.0 × 106 cells/mL was used for
the MAT cell culture. IL-6 concentrations in the incubation
medium were detected using a specific enzyme-linked
immunosorbent assay (ELISA, Novartis in-house), carried
out as described previously (Schindler et al., 2006). Briefly,
100 μL of completed RPMI 1640 medium (see Section 2.5),
50 μL of samples/controls and 100 μL of thawed and washed
PBMC suspension were incubated in a tissue culture plate
(Becton Dickinson, Falcon, Meylan Cedex, France, Cat #
353075) at 37 ± 1 °C for 18–22 h. Then 50 μL of supernatantmedium from each well were transferred to the pre-coated
ELISA plates. The ELISA plates were 96-well microtiter plates
(F96 cert. MaxiSorp Nunc-Immuno plate, Roskilde, Denmark,
Cat # 439454) pre-coated with 2.5 μg/mL mouse monoclonal
anti-hIL-6 antibody (Novartis in-house clone) at 15–25 °C for
24 h and stored in 200 μL of blocking buffer containing
24.2 g/L Tris hydroxymethyl aminomethane (Sigma-Aldrich,
Steinheim, Germany, Cat # 93352) and 10.0 g/L bovine
serum albumin (Sigma-Aldrich, Steinheim, Germany, Cat #
A4503).
Specific signals were detected using sheep anti-IL-6
antibodies and horse radish peroxidase conjugated second-
ary antibodies (kindly donated by H. Gallati, Basel, Switzer-
land). The signals were detected using 200 μL/well of 5% TMB
solution (240 mg Tetramethyl benzidine, Sigma-Aldrich Cat
#87748, 5 mL Acetone, Merck, Darmstadt, Germany, Cat #
K41011314, 45 mL Ethanol, Merck, Cat #K42555183, 300 μl
Hydrogen peroxide solution, Sigma-Aldrich, Cat # 95321).
After 10–15 min, the enzyme reaction was stopped by adding
50 μL/well of 5.4% H2SO4 (Merck, Cat # K42228413)). The
absorbance values were measured at 450 nm using 540 nm
as a reference wavelength on a Synergy HT Multimode
Microplate Reader (BioTek Instruments Corp. Winooski,
Vermont, USA). A standard curve was generated in each
assay in the concentration range 62.5–4000 pg/mL using an
IL-6 standard (hIL-6 rec., Roche Diagnostics, Basel, Switzer-
land, Cat # 11386000001).
2.2.7. Validation design
According to the ICH Harmonized Tripartite guideline this
analytical method belongs to the type: “quantitative tests for
impurities' content” and “limit tests for the control of impurities”
(ICH Guidelines on validation of analytical procedures, Q2(R1)
1995) and, as such, it requires linearity and precision character-
istics for its validation. In addition, we included an additional
validation parameter “Robustness” as related to the quality of
the cryopreserved cells.
3. Results
3.1. Pre-validation
Pre-validation testing aimed to examine the viability and
functional properties (nuclear factor kappa B pathway
activation, differentiation into macrophages, TLR stimulation
and IL-6 production) of the monocytes contained in the
thawed PBMCs when used in a MAT.
3.1.1. Viability
The viability of cryopreserved PBMCs after thawing was
tested using a WST viability assay according to the
manufacturer's instructions (PreMix WST-1, TaKaRa Bio Inc.,
Japan). Briefly, 15 μl of reagent was added to the test wells
and incubated at 37 °C for 3 h in 5% CO2. Optical density was
measured at 570 nm by spectrophotometric analysis and
viability was calculated as sample optical density divided by
control optical density. As a control we used 150 μl of RPMI
medium + 15 μl WST-1. In addition, the cells were stained
with Trypan blue and evaluated using visual light microsco-
py. The viability found was usually more than 80% (data not
shown).
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Since IL-6 used as a readout formonocyte activation has been
reported to be the one of the most highly induced NFκB-
dependent cytokines (Brasier, 2010) and defective NFκB
activation is one of the major reasons for an endotoxin-tolerant
state (Biswas and Lopez-Collanzo, 2009). We examined NFκB
activation in cryopreserved monocytes to test their ability to
generate a signal in response to pyrogenic contamination. The
classical model of NFκB activation requires its translocation
into the cell nucleus. Thus, we examined localization of NFκB
p65 in the cryopreserved monocytes by fluorescent confocal
microscopy.
Fig. 1A shows representative images of the translocation
of NFκB into the nucleus in both endotoxin-treated and drug
substance-treated monocytes but not in untreated cells. Thus
cryopreserved monocytes retained the capability to signal
the presence of pyrogen contamination.
3.1.3. Differentiation of monocytes into macrophages
Cryopreserved PBMC individually isolated from 12 leukocyte
filters (donors)were cultured at 37 °C, 5% CO2 in complete RPMI
1640 Medium for MAT as described in Section 2.2.6. After 20 h,
aliquots of the cell media were taken for MAT assay, and
non-treated PBMCswere further cultured at the same conditions
without media change for 9 days before taking photographs.
Representative light microscopy images of monocytes derived
from 4 donors including 1 non-responder (donor 4) in MAT are
shown in Fig. 1B.
3.1.4. Stimulation of TLRs by their ligands and IL-6 production
The ability of TLRs on the surface of the human
cryopreserved monocytes to bind and be activated by specificA
NFκB (green) Nucleus (blue) Overla
Blank
(neg. ctrl)
Endotoxin
1 EU/mL
(pos. ctrl)
Contaminated
Batch B
Non-
contaminated
Batch A
Fig. 1. NFκB signaling and differentiation in cryopreserved monocytes. A: Translocati
Representative images show translocation of NFκB p65 into the nucleus in croyp
substance. Untreated cells showed only cytoplasmic localization of NFκB p65. B: Diff
Cryopreserved PBMCs were thawed and cultured at 37 °C, 5% CO2 in complete RPM
assay, and non-treated PBMCs were further cultured at the same conditions withou
of monocytes isolated from 4 individuals are shown. Donor 4 was a non-responderTLR ligands was evaluated. Cytokine production in response
to TLR activation was tested using IL-6 as the readout. Each
solution of the TLR ligands was applied at a single concen-
tration within the linear part of the dose–response curves as
established in earlier experiments (data not presented).
The TLR ligands tested included peptidoglycan (5.0 μg/mL),
flagellin (2.0 μg/mL) and PAM3CSK4 (50.0 ng/mL). Reference
standard endotoxin was used at 1.0 EU/mL. The solutions of
endotoxin and other TLR ligands were assayed in quadruplicate
using cryopreserved monocytes from 12 donors (=12 lympho-
cyte filters). IL-6 release into the cultivation medium by the
cryopreserved monocytes in response to TLRs activation was
measured. We observed significant dose–response curves of
fresh PBMCs and cryopreserved PBMCs. The results are present-
ed in Table 3.
In summary, pre-validation testing demonstrated that
cryopreservation itself had no negative effect on the functional
properties of thawed viable monocytes, such as the NFkB
activation pathway, ability to differentiate intomacrophages or
IL-6 production upon TLR stimulation. Thawed monocytes
remained functional and were able to distinguish between
contaminated and non-contaminated samples of the in-house
drug substance. However, detection of pyrogenic contamina-
tion or specific TLR ligands remained dependent on the
recovery of viable cells after cryopreservation. Therefore, we
introduced additional validation parameters for “Robustness”
into the validation process.
3.1.5. Validation
The validation described here was performed with an
in-house drug substance that was produced by fermentation
and where the contamination could be detected neither by LALB
y
Donor 1 Donor 2
Donor 3 Donor 4
on of NFκB into the nucleus upon TLR activation in cryopreserved monocytes.
reserved monocytes in response to a pyrogen-contaminated in-house drug
erentiation into macrophages of cryopreserved PBMCs from different donors.
I 1640 medium. After 20 h, aliquots of the cell media were taken for MAT
t media change for 9 days before taking photographs. Representative images
.
Table 3
Linear response range of fresh vs. cryopreserved PBMCs upon TLR stimulation.
TLR ligand Stock solution Linear range
fresh PBMCs
Linear range
cryo PBMCs
USP reference endotoxin 2000 EU/mL 0.063–1 EU/mL 0.125–2 EU/mL
Endotoxin from P. aeruginosa (donation NIBSC) 40,000 EU/mL 1–50 EU/mL 1–50 EU/mL
Heat-killed S. aureus 1 × 1010 cells/mL 0.5–12.5 × 106 cells/mL 0.5–12.5 × 106 cells/mL
Peptidoglycan from
S. aureus
200 μg/mL 0.3–7.5 μg/mL 0.3–9.0 μg/mL
Synthetic TLR ligand PAM3CSK4 1 mg/mL 5.0–40 ng/mL 5.0–50 ng/mL
Flagellin from
B. subtilis
100 μg/mL 0.625–5.0 μg/mL 0.625–5.0 μg/mL
Linear response ranges in fresh and cryopreserved PBMCs upon TLR stimulation using different ligands. The solutions of endotoxin and other TLR ligands were
assayed in quadruplicates using fresh or cryopreserved PBMC resp. The results are the average from 12 donors. IL-6 release into the cultivation medium in
response to TLRs activation was measured. Significant dose response curves were produced with all ligands tested. There were only little differences in dose–
response curves between fresh PBMCs and cryopreserved PBMCs.
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these two testswere related to both, the chemical characteristics
of the drug substance (ion chelator) and the unknown nature of
the contamination. The response of the PBMCs from individual
donors varies in this special case by a factor of up to ten or even
more and it is therefore not meaningful to calculate standard
deviations. As recommended by statisticians we calculate the
sum of IL-6 responses per donor and use this value for further
evaluation (e.g. mean sum IL-6 responses).3.1.6. Linearity
Two lots of drug substance considered as either “non-
contaminated” (Batch A) or “contaminated” (Batch B) as the
result of earlier testing with fresh PBMCs (i.e. not cryopre-
served),weremixed together in various proportions as shown in
Fig. 2A and tested in the MAT using cryopreserved monocytes
obtained from 12 donors (=12 lymphocyte filters). Since
2 donors out of 12 appeared to be non-responders due to
individual pyrogen sensitivity factors, the results are shown for
10 donors-responders.
Linearity was assessed by testing 5 solutions of these
mixtures covering the range 0%–100% of Batch A and 0%–
100% of batch B. The response was found to be linear, having
a correlation coefficient “r” of 0.990, as shown in Fig. 2B. AA B
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0
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]
Fig. 2. Linear response range of cryopreserved PBMCs. A: Mixtures of non-contamin
contaminated batches A and B were mixed together in the ratios as shown and test
Response of cryopreserved PBMCs expressed as mean sum IL-6 from 10 donors sho
assessed individually and his sum of IL-6 release in response to each of 5 tested copreviously set acceptance criterion (r ≥ 0.8) was fulfilled and
satisfactory for each set of measurements.3.1.7. Intermediate precision
Two lots of drug substance considered as “non-contaminated”
(Batch A) and “contaminated” (Batch B) from earlier testing,
were tested in MAT using cryopreserved monocytes from 10
donors (lymphocyte filters).
Drug substance batch SM0100 was used as a reference
substance in method C according to Pharm. Eur. 2.6.30
(European Pharmacopeia, 2010). The test solutions were
tested in quadruplicates at concentrations of 7.5 mM, 15 mM,
30 mM, and 60 mM in LAL reagent water. The testing was
performed by two analysts on different days with the same
donations of cryopreserved PBMCs. The results of the interme-
diate precision test are presented as themean sum IL-6 (Fig. 3A)
in response to contamination and as the median ratio to
the reference substance (Fig. 3B) for each substance tested.
The donor effect is largely normalized by using the reference
substance comparison evaluation procedure. Median ratios
below 2.5 are considered as negative reactions, ratios above 2.5
as positive reactions.
The acceptance criterion “the conclusion of different,
independent experimental runs should be the same” is500
400
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ed in the MAT for linearity using PBMCs from 10 donors. B: Linearity graph.
ws a linear function with a correlation coefficient r = 0.99. Each donor was
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Fig. 3. Testing of intermediate precision. The test solutions of non-contaminated and contaminated batches A and B respectively, were tested in quadruplicates by
two analysts on different days with the same groups of the cryopreserved PBMCs. Batch A (analyst 1), Batch B (analyst 1), Batch A (analyst 2), Batch B (analyst 2).
A: Release of IL-6 (IU/mL) by PBMCs from individual donors is presented as the sum of IL-6 concentrations at the test concentrations of 7.5 mM, 15 mM, 30 mM
and 60 mM (Σ IL-6) for non-contaminated and contaminated test substances. ♦ batch A (analyst 1), ■ batch B (analyst 1), Δ batch A (analyst 2), ○ batch B
(analyst 2). B: The ratio was calculated for each test substance as the result of Σ IL-6 of the test substance divided by ΣIL-6 of the reference substance. Drug
substance reference standard was used. The substance passes the test when the median ratio is below 2.5, otherwise it fails. ♦ batch A (analyst 1) — median
ratio = 1.25, ■ batch B (analyst 1) — median ratio = 16.5, Δ batch A (analyst 2) — median = 1.0, ○ batch B (analyst 2) — median ratio = 12.5.
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“non-contaminated” batch A and the “contaminated” batch B.
3.1.8. Viability and robustness
As recovery of monocytes after thawing of cryopreserved
cells might vary depending on the handling, the reliability of
testing was validated with respect to the monocyte cell count.
Cryopreserved PBMCs from 6 randomly chosen donors
were used in the MAT with drug substance reference standard
SM0100 and with contaminated drug substance batch B.
Solutions were prepared at 3 different concentrations:
15 mM, 30 mM, and 60 mM, and tested in quadruplicates.
Cryopreserved PBMCs were used in the MAT at following
concentrations: 0.70 × 106 cells/mL, 1.00 × 106 cells/mL, and
1.50 × 106 cells/mL.
The results are summarized as mean sum IL-6 from 6
donors in response to contamination (Fig. 4A) and as the
median ratio for each substance (Fig. 4B) with IL-6 responses
compared for the different concentrations of PBMCs used.
The robustness of the method was considered acceptable
because the acceptance criterion (at least 1.00 × 106 cells/M
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Fig. 4. Assessment of required cell number for the detection in MAT. Cryopreserved
contaminated drug substance tested at 15 mM, 30 mM and 60 mM in quadruplicat
PBMCs from individual donors is presented as the mean sum of IL-6 concentrations s
60 mM (Σ IL-6). Concentrations of released IL-6 are shown for PBMCs used in the MA
B: The ratio was calculated for contaminated test substance as the result of Σ IL-6 of
The median ratio (n = 6) for contaminated batch B/non contaminated batch
1.00 × 106 cells/mL and 6.9 at 0.70 × 106 cells/mL. ♦ donor 1, ◊ donor 2, ▲ donor 3mL should be able to distinguish between non-contaminated
and contaminated lots) was fulfilled and satisfactory for all 6
donors.
In summary, validation testing showed that the cryopres-
ervation methodology is able to deliver cells that specifically
detect pyrogenic/pro-inflammatory contamination in MATs
that fulfill acceptance criteria for linearity, precision and
robustness. In addition, the methodology was able to detect a
pyrogenic contamination in the in-house drug substance,
otherwise non-detectable in the bacterial endotoxin test or
rabbit pyrogen test.
3.2. Examples of the practical application of the MAT using
cryopreserved PBMCs
After successful completion of the validation with a drug
substance made by fermentation, a very different product, a
vaccine in final dosage form, was tested. For the vaccine the
chosen methodology was method A as described in Pharm.
Eur. 2.6.30 (European Pharmacopeia 2010) and the stan-
dard curve of reference standard endotoxin covered theR
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Fig. 5. Method adjustment based on the nature of the test sample. A: Time of cryopreservation and performance of PBMCs (Stability of cryopreserved PBMCs).
Three batches of a vaccine containing different degrees of pyrogenic activity were tested in the MAT using PBMCs which had been stored for approx. 2 months or
approx. 12 months in liquid nitrogen. The mean endotoxin equivalent per mL were calculated. The coefficient of variation for time point 2 months was for ♦ batch
201: 40.7%, for □ batch 701: 51.3%, for ▲ batch X38: 35.8%; for time point 12 month for batch 201:17.9%, for batch 701: 38.4% and for batch X38:35.8%. B:
Monocyte activation test on Poly (DL-lactide-coglycolide). Nine batches of a polymer excipient, not soluble in water, were tested in the MAT using cryopreserved
PBMCs. The reference standard endotoxin calibration curve following the statistical fitting parameters of r b 0.980 was used for all calculations. The results of 9
individual batches were ≤0.07 endotoxin equivalents/mL (for each batch) demonstrating that the batches themselves were not contaminated. The % of reference
endotoxin spike recovery (0.5 EU/mL) for each batch and each donor is presented. The target range for spike recovery from 50 to 200% was met (rare exceptions
discussed in the text).Δ Unspiked sample, □ spiked sample, and ▲ mean recovery %.
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statistical evaluation was performed by applying parallel
line assay methodology (Pharm. Eur. 5.3.) The vaccine
consisted of three recombinant proteins and outer mem-
brane vesicles from a gram-negative bacterium and includ-
ed aluminum hydroxide as adjuvant.
The vaccine was diluted in RPMI medium (completed
with 1% human serum AB, 1% L-glutamine 200 mM and 2%
penicillin/streptomycin solution) in the ratio of 1 in 200, 1 in
800, 1 in 3200 and 1 in 12,800 in order to cover a wide range
of possible reactivity. Since the vaccine contains intrinsic
bacterial endotoxin, spiking of the samples with reference
standard endotoxin was inappropriate. The test was able to
detect pyrogenic contamination using both cryopreserved
PBMCs stored in liquid nitrogen for approx. 2 months and
cryopreserved PBMCs stored for approx. 12 months. The
results for three batches of a medicine with different levels of
pyrogenic contamination are shown in Fig. 5A. The coefficient
of variation amongst donors ranged from 17.9% to 51.3%.
Despite the fact that, for technical reasons, PBMC from
different donors were used to generate the data for the two
different time points, it was shown that storage in liquid
nitrogen for 12 months did not reduce the quality of the
cryopreserved PBMCs and the results using these cells were
not significantly different from results obtained with
PBMCs stored for only 2 months (T-test, p-value for batch
201: p = 0.682, for batch 701: p = 0.810 and for batch
X38: p = 0.406).
Thus, MAT with cryopreserved PBMCs was successfully
adjusted for the testing of vaccine containing intrinsic
endotoxin and cryopreserved PBMCs proved to remain stable
after 2 and 12 months of storage in liquid nitrogen.
Another successful example of using cryopreserved PBMCs
included the testing of a hydrophobic polymer excipient which
is used in the pharmaceutical industry in the manufacture of
injectable suspensions and, therefore, requires a test for
pyrogenic contamination. The chosen methodology wasmethod A as described in Pharm. Eur. 2.6.30 (European
Pharmacopeia 2010). Spiking of the samples with 0.5 EU/mL
reference standard endotoxin was included as a positive
product control to ensure the suitability of the MAT using
cryopreserved PBMCs for pyrogen detection. For this
purpose, the samples of polymer were dissolved in DMSO
and further diluted in completed RPMI medium to concen-
trations of 0.2 mg/mL and 0.02 mg/mL of polymer, and then
tested either unspiked or spiked. The residual concentrations of
the organic solvent in the test wells were 0.5% or 0.05%,
respectively. The reference standard endotoxin calibration
curve following the statistical fitting parameters of r N 0.980
was used for all calculations. The result for each of the 8
individual batches was ≤0.07 endotoxin equivalents/mL. The
result and the spike recovery (0.5 EU/mL) for each batch and
each donor is presented in Fig. 5B. The target range for spike
recovery from 50 to 200% was met with only very few
exceptions. We assume that in rare cases where the spike
recovery was slightly above 200%, the PBMCs reacted with
residues of DMSO since the stock solution of the polymers had to
be prepared in that solvent in order to completely dissolve the
test sample (Xing and Remick, 2005).4. Discussion
Despite the official acceptance of theMAT for pyrogen testing
(European Pharmacopoeia, 2010), its introduction and use is
limited by regulatory and practical restrictions related to the
handling of fresh human blood and associated phlebotomy
(Schindler et al., 2009). Therefore, the work described above
focused on a phlebotomy-free alternative by exploring the
possibility of using monocytes isolated from lymphocyte filters
usually treated as biological waste in hospitals and blood
donation centers. Seeking to avoid handling of the fresh human
blood in the BL2-level laboratories usually involved in pyrogen
testing, we developed an MAT using cryopreserved PBMCs with
190 A. Koryakina et al. / Journal of Immunological Methods 405 (2014) 181–191the potential for easier implementation and use in quality
control laboratories for pyrogen testing.
Since this methodology was developed in the frames of an
industrial Six Sigma project and aimed at a method validation
as a final target, we were unable to follow up a number of
experimental questions that arose. Some results which were
not followed up further, are described as “observations” in
Sections 2.1.1 to 2.1.7.
Performing theMATwithmonocytes from individual donors
rather than using monocyte pools allows the assessment of a
wide range of responses based on individual sensitivity to
pyrogens and to observe much wider differentiation of
individual donor responses to non-endotoxin pyrogens com-
pared with endotoxin. This approach helps us to identify and
eliminate from the calculation model low responders and
non-responders whose inclusion can potentially lead to false
negative results when taken into consideration as part of the
pool. For standardization purposes, we identified the linear part
of the dose–response curves for several non-endotoxin pyro-
gens as shown in Table 3. We hope that further research on
equivalence of responses to endotoxin and non-endotoxin
pyrogens by single individuals will allow establishing a robust
mathematicalmodel for pyrogen acceptance limits based on the
nature of contaminant.
As main advantages of the MAT using cryopreserved
PBMC and IL-6 readout are presented in this paper, we
consider easier access to PBMC from leukocyte filters with
phlebotomy-related safety issues covered by the hospitals
and blood donation centers and timely independency of
testing fromblood donations due to availability of cryopreserved
PBMC. Additionally, this method provides an opportunity for
multiple sample testing and repeated assays with same
material/donor thanks to up to 10 times higher amounts of
monocytes harvested from one lymphocyte filter if compared to
laboratory blood donation. Contrary to the cryopreserved whole
blood, cryopreservation of PBMC has the advantage of the
possibility to performwashing steps to eliminate cryoprotectant
containing DMSO (Fahy, 1986; Arakawa et al., 1990) and cell
debris. Furthermore, the PBMC suspensions do not contain
erythrocytes allowing cell count in transparent suspensions and
setting up the assay more precisely.
5. Conclusion and outlook
So far the MAT is the best alternative method to the rabbit
pyrogen test to detect both, endotoxin and non-endotoxin
pyrogens in pharmaceutical medicines and vaccines. Howev-
er, one of the main hurdles and the major reason for the
limited application of the MAT to date is the access to human
monocytes. The methodology for cryopreservation of human
monocytes in form of PBMCs described above, transforms the
MAT into an easier analytical test method. Nevertheless, it
has to be emphasized that every new product has to undergo
a product specific validation. Depending on the properties of
the product, the validation is to address all that is likely to
influence the outcome of the test: interference by the test
product (obviously), but also accuracy, precision, linearity
and robustness.
If the pyrogenic/pro-inflammatory contamination in a
pharmaceutical product is not clearly identified, or even if it
likely arises from several different contaminants in variableproportions, then the MAT using fresh PBMCs or cryopreserved
PBMCs from individual donors is strongly recommended. A
biostatistician should be consulted to establish an evaluation
method that takes all aspects of the analysis into consideration.
Such a MAT with individual donors delivers much more
information compared with MATs that use a pool of PBMCs or
a pool of whole blood. The reason for this is that individual
donor responses to non-endotoxin pyrogens differ widely (in
contrast to responses to endotoxin). So, for a safe and stringent
release method we need to make use of the extremes of the
responses of different donors. It is our belief that widespread
adoption of the above cryopreservationmethodology will allow
the MAT to be established in more QC/QA laboratories and will
permit a clearer picture to emerge of the nature and pattern of
non-endotoxin pyrogenic contamination in pharmaceuticals.
Another application of cryo-PBMCs is to serve as an
alternative to freshly isolated PBMCs in the tests that are
being developed for unwanted intrinsic pro-inflammatory
activities of new biological therapeutics, e.g. monoclonal
antibodies (Stebbings et al., 2007; Findlay et al., 2011). Such
tests use PBMCs or PBMCs over a layer of endothelial cells to
detect (unwanted) cytokine release. As with the MAT, PBMCs
are more suited to this purpose than tests using whole blood
(Findlay et al., 2010; Thorpe et al., 2013a, 2013b).Acknowledgments
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